Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients

Author(s): Engy A. Wahsh*, Amal K. Hussein, Ahmed A. Gomaa, Mohamed A. Baraka and Mohie Al-deen Abead

Volume 20, Issue 1, 2020

Page: [43 - 48] Pages: 6

DOI: 10.2174/1871526518666180716141806

Price: $65

conference banner
Abstract

Background: Chronic infection with Hepatitis C virus (HCV) is considered as a major cause for developing liver cirrhosis and hepatocellular carcinoma. A new era in HCV treatment is ongoing using Direct Acting Antiviral activity (DAA). The first approved DAA drug was Sofosbuvir which has a high tolerability and preferable pharmacokinetic profile. Another recently developed drug is Daclatasvir a first-in-class HCV NS5A replication complex inhibitor. Both drugs are administered orally once daily and have potent antiviral activity with wide genotypic coverage.

Methods: In the outpatient clinic, one hundred and fifty naïve difficult to treat chronic HCV patients were recruited from Tropical Medicine Department at Fayoum public hospital. A combination of Daclatasvir (60 mg) and Sofosbuvir (400 mg) (DCV/SOF) has been administered for those patients once daily with Ribavirin (1200 mg or 1000 mg based on patients’ weight on two divided doses) over a period of 12 weeks. All patients have been followed up for clinical, laboratory assessment and HCV PCR to detect the efficacy and safety of the therapy.

Results: Sustained Virologic Response rate (SVR12) was achieved in the vast majority of patients (90.67%). Cirrhotic patients showed lower SVR compared to non-cirrhotic patients (88.89% vs 90.91%, respectively). Around half of the patients (49.33%) developed adverse events (AEs) during treatment. The most common AEs were headache, fatigue and abdominal pain.

Conclusion: The available evidence seems to suggest that combination therapy of (DCV/SOF with RBV) in the treatment of chronic HCV genotype IV naïve difficult to treat patients either cirrhotic or non-cirrhotic is safe and effective. Monitoring for clinical and laboratory hepatic parameters was the basis for these findings.

Keywords: Chronic hepatitis C, daclatasvir, sofosbuvir, ribavirin, difficult to treat, hepatocellular carcinoma, inhibitor.

[1]
Hanno, A.; Elwazzan, D.; Ibrahim, M.; Hafez, R. A real life study on treatment of egyptian patients with HCV genotype iv with Simeprevir and Sofosbuvir. Health (Irvine Calif.), 2016, 8, 780-786.
[http://dx.doi.org/10.4236/health.2016.89082]
[2]
Sievert, W.; Altraif, I.; Razavi, H.A.; Abdo, A.; Ahmed, E.A.; Alomair, A.; Amarapurkar, D.; Chen, C.H.; Dou, X.; El Khayat, H.; Elshazly, M.; Esmat, G.; Guan, R.; Han, K.H.; Koike, K.; Largen, A.; McCaughan, G.; Mogawer, S.; Monis, A.; Nawaz, A.; Piratvisuth, T.; Sanai, F.M.; Sharara, A.I.; Sibbel, S.; Sood, A.; Suh, D.J.; Wallace, C.; Young, K.; Negro, F. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int., 2011, 31(Suppl. 2), 61-80.
[http://dx.doi.org/10.1111/j.1478-3231.2011.02540.x] [PMID: 21651703]
[3]
Eletreby, R.; Elakel, W.; Said, M.; El Kassas, M.; Seif, S.; Elbaz, T.; El Raziky, M.; Abdel Rehim, S.; Zaky, S.; Fouad, R.; Gamal Eldeen, H.; Abdo, M.; Korany, M.; Yosry, A.; El Serafy, M.; El-Sayed, M.H.; ElShazly, Y.; Waked, I.; Doss, W.; Esmat, G. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int., 2016, 1-8.
[http://dx.doi.org/10.1111/liv.13266] [PMID: 27712017]
[4]
Centre for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). 2012, 61(29)
[5]
El-Akel, W.; El-Sayed, MH.; El Kassas, M.; El-Serafy, M.; Khairy, M.; Elsaeed, K.; Kabil, K.; Hassany, M.; Shawky, A.; Yosry, A.; Shaker, MK.; ElShazly, Y.; Waked, I.; Esmat, G.; Doss, W. National treatment programme of hepatitis C in Egypt Hepatitis C virus model of care, 2017, 24(4), 262-267.
[http://dx.doi.org/10.1111/jvh.12668] [PMID: 28145032]
[6]
Messina, J.P.; Humphreys, I.; Flaxman, A.; Brown, A.; Cooke, G.S.; Pybus, O.G.; Barnes, E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology, 2015, 61(1), 77-87.
[http://dx.doi.org/10.1002/hep.27259] [PMID: 25069599]
[7]
Omar, H.; El Akel, W.; El, T.E.M. Generic Daclatasvir plus Sofosbuvir, with or without Ribavirin, in treatment of chronic hepatitis C : real-world results from 18 378 patients in Egypt. Aliment. Pharmacol. Ther., 2017, (August), 1-11.
[http://dx.doi.org/10.1111/apt.14428] [PMID: 29193226]
[8]
Kamal, S.M.; Nasser, I.A. Hepatitis C genotype 4: What we know and what we don’t yet know. Hepatology, 2008, 47(4), 1371-1383.
[http://dx.doi.org/10.1002/hep.22127] [PMID: 18240152]
[9]
Flamm, S.L. Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015 The 50th Annual Meeting of the European Association for the Study Table of Contents. Gastroenterol Hepatol Indep peer-reviewed J, 2015, 11(6), 1-23.
[10]
Hassanein, T.; Sims, K.D.; Bennett, M.; Gitlin, N.; Lawitz, E.; Nguyen, T.; Webster, L.; Younossi, Z.; Schwartz, H.; Thuluvath, P.J.; Zhou, H.; Rege, B.; McPhee, F.; Zhou, N.; Wind-Rotolo, M.; Chung, E.; Griffies, A.; Grasela, D.M.; Gardiner, D.F. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J. Hepatol., 2015, 62(5), 1204-1206.
[http://dx.doi.org/10.1016/j.jhep.2014.12.025] [PMID: 25559328]
[11]
Welzel, T.M.; Petersen, J.; Herzer, K.; Ferenci, P.; Gschwantler, M.; Wedemeyer, H.; Berg, T.; Spengler, U.; Weiland, O.; van der Valk, M.; Rockstroh, J.; Peck-Radosavljevic, M.; Zhao, Y.; Jimenez-Exposito, M.J.; Zeuzem, S. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut, 2016, 65(11), 1861-1870.
[http://dx.doi.org/10.1136/gutjnl-2016-312444] [PMID: 27605539]
[12]
Abergel, A.; Metivier, S.; Samuel, D.; Jiang, D.; Kersey, K.; Pang, P.S.; Svarovskaia, E.; Knox, S.J.; Loustaud-Ratti, V.; Asselah, T. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology, 2016, 64(4), 1049-1056.
[http://dx.doi.org/10.1002/hep.28706] [PMID: 27351341]
[13]
Sulkowski, M.S.; Gardiner, D.F.; Rodriguez-Torres, M.; Reddy, K.R.; Hassanein, T.; Jacobson, I.; Lawitz, E.; Lok, A.S.; Hinestrosa, F.; Thuluvath, P.J.; Schwartz, H.; Nelson, D.R.; Everson, G.T.; Eley, T.; Wind-Rotolo, M.; Huang, S.P.; Gao, M.; Hernandez, D.; McPhee, F.; Sherman, D.; Hindes, R.; Symonds, W.; Pasquinelli, C.; Grasela, D.M. AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med., 2014, 370(3), 211-221.
[http://dx.doi.org/10.1056/NEJMoa1306218] [PMID: 24428467]
[14]
U.S. Food and Drug Administration. SOVALDITM (Sofosbuvir) pre- scribing information, 2014. Available from: http://www.accessdata.fda.gov/drusafda_docs/label/2013/204671s000lbl.pdf
[15]
Gane, E.J.; Hyland, R.H.; An, D.; Svarovskaia, E.; Pang, P.S.; Brainard, D.; Stedman, C.A. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology, 2015, 149(6), 1454-1461.e1.
[http://dx.doi.org/10.1053/j.gastro.2015.07.063] [PMID: 26261007]
[16]
Kanda, T.; Nakamoto, S.; Sasaki, R.; Nakamura, M.; Yasui, S.; Haga, Y.; Ogasawara, S.; Tawada, A.; Arai, M.; Mikami, S.; Imazeki, F.; Yokosuka, O. Sustained Virologic Response at 24 weeks after the end of treatment is a better predictor for treatment outcome in real-world HCV-infected patients treated by hcv ns3/4a protease inhibitors with p Peginterferon plus ribavirin. Int. J. Med. Sci., 2016, 13(4), 310-315.
[http://dx.doi.org/10.7150/ijms.14953] [PMID: 27076789]

Rights & Permissions Print Cite
Article Metrics
23
2
© 2024 Bentham Science Publishers | Privacy Policy